Jennison Associates
OVID icon

Jennison Associates’s Ovid Therapeutics OVID Stock Holding History

Jennison Associates’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-394,436
Closed -$3.08M – 686
2018
Q2 		$3.08M Sell
394,436
-256,220
-39% -$2.2M ﹤0.01% 515
2018
Q1 		$4.6M Buy
650,656
+72,651
+13% +$588K ﹤0.01% 493
2017
Q4 		$5.71M Sell
578,005
-89,461
-13% -$821K 0.01% 492
2017
Q3 		$5.86M Buy
667,466
+17,392
+3% +$145K 0.01% 502
2017
Q2 		$6.74M Buy
+650,074
New +$8.49M 0.01% 500

Other funds holding OVID

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Jennison Associates's OVID Position: Q3 2018 in Review

Jennison Associates sold out of Ovid Therapeutics (OVID) in Q3 2018, closing a stake of 394,436 shares — an estimated $3.08M sold.

Jennison Associates first reported a position in OVID in Q2 2017 and held it in 5 quarters. The position peaked at $6.74M in Q2 2017. 49 funds tracked by Wall St. Rank hold OVID as of Q3 2018.

  • Jennison Associates reported no remaining Ovid Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Jennison Associates sold 394,436 Ovid Therapeutics shares in Q3 2018, an estimated $3.08M.
  • Jennison Associates first reported a position in Ovid Therapeutics in Q2 2017 and held it in 5 quarters.
  • Jennison Associates's Ovid Therapeutics position peaked at $6.74M in Q2 2017.
  • 49 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2018.

Based on Jennison Associates's 13F filing for Q3 2018, filed 8 Nov 2018.